Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.